Email  LinkedIn  Web

February 18, 2026



HRSA’s latest Request for Information (RFI) offers a significant opportunity for stakeholders to help inform the development of a 340B Rebate Model Pilot Program. 


HRSA recently announced a Request for Information, 340B Rebate Model Pilot Program. The agency’s stated goal is “to gather input from interested parties regarding the potential use of rebates to effectuate the ceiling price under the 340B Program, including the standards and procedures that should govern the approval of manufacturer rebate plans and impacts on all stakeholders.” 


Through this RFI, HRSA is inviting comments from parties throughout the drug supply chain, including covered entities, manufacturers, wholesalers, State Medicaid agencies, pharmacies, the Federal Government, and other groups. 


All public comments must be submitted by Thursday, March 19, 2026.


Please submit your comments through the Federal eRulemaking portal: https://www.regulations.gov 


Be sure to include HHS Docket number HRSA-2026-03042 with your submission.


HRSA has identified several key areas for comment, particularly for covered entities (see pages 5-10). These areas include administrative expenses, cash flow challenges, operational costs, software development needs, potential impacts on patients, and data collection requirements by covered entities (are data elements readily available-what data is coming directly from the CE, or by existing third-party vendors).


We’re here to help you compile and structure information to strengthen your comment submission. Contact BluePeak today

BluePeak Advisors | www.bluepeak.com

Email  LinkedIn  Web

BluePeak Advisors is a division of Gallagher Benefit Services, Inc.